Genfit S.A.

General Information
Business:

(Note: Public offering: “Our ordinary shares are listed on Euronext Paris under the symbol “GNFT.” On March 13, 2019, the last reported sale price of our ordinary shares on Euronext Paris was €23.42 per ordinary share, equivalent to a price of $26.33 per ADS, assuming an exchange rate of €0.8894 per U.S. dollar, the exchange rate on March 8, 2019. )

We are a late-stage clinical biopharmaceutical company dedicated to the discovery and development of innovative drug candidates and diagnostic solutions targeting metabolic and liver-related diseases where there is considerable unmet medical need. We are a leader in the field of nuclear receptor-based drug discovery with a rich history and strong scientific heritage spanning almost two decades. We are evaluating our most advanced drug candidate, elafibranor, in a pivotal Phase 3 clinical trial as a potential treatment for nonalcoholic steatohepatitis, or NASH, and as a potential treatment for primary biliary cholangitis, or PBC.

Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES)
Employees: 148
Founded: 1999
Contact Information
Address Parc Eurasanté, 885 avenue Eugène Avinée, 59120 Loos, France
Phone Number +33 3 20 16 4000
Web Address http://www.genfit.com
View Prospectus: Genfit S.A.
Financial Information
Market Cap $952.7mil
Revenues $8.5 mil (last 12 months)
Net Income $-89.9 mil (last 12 months)
IPO Profile
Symbol GNFT
Exchange NASDAQ
Shares (millions): 5.0
Price range $26.33 - $26.33
Est. $ Volume $131.7 mil
Manager / Joint Managers SVB Leerink/ Barclays
CO-Managers Bryan, Garnier/ Natixis/ Roth Capital Partners/ H.C. Wainwright & Co.
Expected To Trade: 3/27/2019
Day: Wednesday
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change